Total Voting Rights

Assura PLC
30 April 2024
 

30 April 2024

Assura plc

Total Voting Rights

In conformity with the FCA's Disclosure Guidance and Transparency Rules DTR 5.6.1 we hereby notify that the company's issued share capital consists of:

Issued shares and voting rights
2,989,454,390 ordinary shares of 10 pence each ("Shares")

The above figure of 2,989,454,390 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, shares of Assura plc under the FCA's Disclosure and Transparency Rules. No shares are held in treasury.

- Ends -

 

For more information, please contact:

 

Assura plc

 

Tel: 0161 515 2043

David Purcell, Investor Relations Director

 

Email: Investor@assura.co.uk

FGS Global

Gordon Simpson

Tel: 0207 251 3801

Email: Assura@fgsglobal.com

 

Notes to Editors

Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which over six million patients are served.

A constituent of the FTSE 250 and the EPRA* indices, as at 30 September 2023, Assura's portfolio was valued at £2.7 billion.

At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026. 

Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association
Assura plc LEI code: 21380026T19N2Y52XF72

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Assura (AGR)
Investor Meets Company
UK 100